The Abu Dhabi Health Services Company “SEHA” under the supervision of the Health Department in Abu Dhabi, in cooperation with “G42 Healthcare”, a subsidiary of the “G42” group and the company “Synopharm CNBG”, conducted new experiments for the third phase of the inactive vaccine of the epidemic “Covid” -19 ", in line with the vision of the rational leadership and its commitment to overcoming this global epidemic.
The global clinical trials for the third phase of a possible vaccine come as a result of the international cooperation efforts that Abu Dhabi is embracing within the framework of the commitment of the UAE government and health organizations to find a cure for the greatest challenge humanity has witnessed in the twenty-first century.
Acting Undersecretary of the Abu Dhabi Health Department, Dr. Jamal Mohammed Al Kaabi, said: "The diversity of nationalities in the homeland of humanity in the UAE was the reason for being the perfect place to conduct the third stage of clinical trials, as well as the great role our wise leadership and efforts in addressing the Covid-19 virus have played in various Countries of the world".
He praised the great cooperation and demand for volunteering from a large number of citizens and residents. Today, a number of volunteers have advanced to more than 20 nationalities, which will contribute to enhancing these experiences and the feasibility of applying the vaccine.
For its part, the Executive Medical Director of Sheikh Khalifa Medical City affiliated with SEHA and Chair of the National Clinical Committee for "Covid-19" Dr. Nawal Al-Kaabi stressed the leadership's keenness to provide health support to all members of society and make efforts to provide the necessary vaccine to combat the Corona virus The newcomer / Covid-19 / calling on everyone who resides on the good land of the UAE to volunteer and participate for humanity in these clinical trials that will have an important role in reaching the desired results to prove the safety and effectiveness of the vaccine, to be added to the record of the history of the UAE's achievements and outstanding contributions in the health field on World level.
She said that "SEHA" has provided a number of specialized health practitioners to supervise these experiments, and has designated several centers to complete the experiments on volunteers who have registered their names and from the various nationalities residing in the UAE, led by UAE citizens of both sexes.
It is remarkable that the numbers of registrants to participate in clinical trials is increasing day by day, as today it has reached 10 thousand volunteers and the matter is available for those who wish to volunteer to register through the link designated for that which is / www.4humanity.ae/ where the volunteer is given the inactive inoculation of "Covid" 19- Then it is continuously followed up to examine the results and whether there is a reaction in the bodies of the volunteers, provided that the scientific team draws the results for the current stage after completing the experiment on the volunteers.
The process of follow-up of volunteers is also carried out in an intensive way, according to the approved protocol, provided that the volunteer undergoes a health evaluation process before entering into the study, as there are diseases that are completely excluded, as well as those who were previously infected with the Covid-19 virus are excluded.
The volunteers will be followed up extensively and will last for 42 days, which requires a schedule of visits to clinical trial centers for a number of at least 17 visits to monitor the health situation and research the results of the vaccine. In addition, the volunteer will be directed not to travel during this period. There will also be periodic follow-up and remote medical consultations that may reach 6 months.
The Department of Health Abu Dhabi, in cooperation with SEHA and G42 Healthcare, is looking to conduct clinical trials of the vaccine for 15,000 volunteers, so that about 5,000 tests will be carried out in the first stage in order to ensure the effectiveness of the program, as the UAE has been chosen as a preferred destination for the third stage trials of the inactive vaccine Being an appropriate environment for that to provide 200 different nationalities in which to reside, which enables strong research on diverse races and contributes to enhancing the feasibility of application at the global level when the experiments succeed.
The volunteer Hamad Al Balushi, from the Emirates, expressed his happiness to be one of the first volunteers to complete this clinical experience. He also expressed his wishes that these experiments succeed and benefit the Emirates and the world at large. And all those working in these experiences, praying to God that their efforts be successful.
For his part, Emirati volunteer Mohammed Al Kaabi, a university student at Abu Dhabi University, said that he is proud to be one of the first volunteers in the third stage of clinical trials of the inactive vaccine for the "Covid-19" epidemic and expressed his wishes that these experiments will succeed and benefit the UAE and the world and that the world be I collect safely from the Covid-19 virus.
From the Sultanate of Oman, the volunteer, Jamila, said that the UAE and its wise leadership taught us to always be proactive for good. From this standpoint, I am proud to be one of the first volunteers for humanity and I invite everyone to volunteer for humanity, and I take the opportunity to thank the health sector in Abu Dhabi for all the efforts they made. For the safety of society and this vaccination for the sake of humanity, we are very proud and, God willing, we can always raise the UAE flag high.
The third clinical trial phase follows the success of the first and second stages in China and the third stage will be open to volunteers between the ages of 18 and 60 who live in Abu Dhabi and Al Ain.
These experiences are the result of cooperation between the health sector in the UAE and each of the "G42 Healthcare Company", one of the companies affiliated to the "G42" group, which is headquartered in Abu Dhabi and occupies a leading position in efforts to tackle the pandemic of "Covid-19" and the company "Cinopharm C" NBG is the sixth largest vaccine producer in the world and the company ranked 169 on the Fortune 500 Global List of 2018.
It is mentioned that a 24/7 emergency helpline was assigned to all volunteers in these clinical trials and it is managed by Abu Dhabi Health Services Company / Health / on the number 02 819 1111.